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Abstract
During HIV-1 infection, cytotoxic T cell (CTL) responses exert strong selective pressure on the
replicating virus population. Here we report evidence for T cell activity against the drug resistant
K103N region of viral reverse transcriptase in three HIV-1 infected patients exposed to NNRTI
antiretroviral drugs. We further characterize the response in one patient by ELISPOT analysis. A
nine amino acid peptide incorporating 103N was recognized by patient T cells whereas the wild
type was not. The RT K103N mutation is selected by the NNRTI class of HIV drugs. We
hypothesize that, in certain individuals, CTL responses against 103N-containing epitopes may
protect against NNRTI drug resistance. Characterizing such responses in the context of HLA
subtypes could lead to tailored HIV drug therapy or to the design of therapeutic vaccines.
Findings
During HIV-1 infection, anti-viral CTL responses develop
and persist [1,2]. Unfortunately, CTL escape mutations are
selected, helping the virus evade immune surveillance [3-
5]. Almost every region of the HIV proteome can serve as
a CTL target, including RT [6]. However, individual class I
HLA alleles restrict 8–10 amino acid epitopes such that
individuals vary in CTL epitope usage [8].
A few studies have demonstrated CTL responses directed
against HIV drug resistance mutations. An HLA-A2-
restricted RT epitope including the lamivudine-associated
M184V mutation has been characterized [9]. In another
study, epitopes incorporating M41L, L74V, M184V and
T215Y in RT were demonstrated by ELISPOT [10]. Finally,
Karlsson and colleagues have shown that a drug-resistant
mutant region in HIV protease can be a CTL target [11].
These studies suggest a dynamic interaction between anti-
viral immune responses and the selection of drug resist-
ance mutations during therapy.
The K103N mutation is a common cause of RT NNRTI
drug resistance. Clinically, this mutation is potent as a sin-
gle mutation and causes cross resistance to drugs in this
class [12]. We hypothesized that certain individuals can
mount T cell responses against epitopes incorporating
103N. If true, then individuals lacking such responses
might be predisposed to developing drug resistance at this
site.
We recruited 10 patients, 6 men and 4 women, chroni-
cally infected with HIV-1 who were exposed to the NNRTI
drug efavirenz. The study was approved by the Washing-
ton University Human Studies Committee, Study #04-
1207. All patients had recent negative serology for hepati-
tis C and were without fever. Blood samples were drawn
after informed consent was obtained. Subjects ranged in
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age from 30–60 years old with CD4 counts between 334–
786 × 103 cells/ml. 9 had undetectable HIV RNA levels
(less than 40 copies/ml) by the Roche Amplicor assay
(Roche Diagnostics) within the last 6 months and had no
evidence of K103N on a standard HIV genotype (Quest
Diagnostics) within the last 5 years. The tenth, subject 2,
had a recent viral load of 2,000 copies/ml on a non-
NNRTI based regimen and had evidence of circulating
K103N by genotype 8 months prior to the study.
A second sample was drawn for subject 6705A 12 months
after the initial blood draw. Subject 6705A is a 30 year old
African American woman diagnosed with HIV in 2002.
She initiated a regimen of lamivudine, AZT and efavirenz
in October of 2004, at which time a viral load was 34,600
copies/ml with a CD4 count of 230 × 103 cells/ml. Within
two weeks she developed severe nausea and vomiting.
One week later, ectopic pregnancy was discovered requir-
ing surgery and withholding of antiviral medications. She
restarted therapy but continued to miss doses. As of
December, 2004, and April, 2005, the viral loads
remained less than 150 copies/ml, increasing to a range of
1,000–2,000 copies/ml by April and May, 2004. In
November 2005, K103N was detected on a standard gen-
otype, at which time the viral load was 5,100 copies/ml.
Peptides were designed based on published sequences
[13] and known consensus drug resistance mutations.
Peptides were synthesized by Sigma Genosys (The Wood-
lands, TX) at 96–99% purity as follows: KKKKSVTVL,
KKNKSVTVL, HPAGLKKKK, HPAGLKKNK, LGIPH-
PAGLKKNKSVTVL, GLKKNKSVTVLDVGDAYF, GLKKKKS-
VTVLDVGDAYF with the underlined residue representing
position 103 in RT. The control peptide was AASIRLRPG-
GKASASA. Stock solutions were made by resuspending
peptides in water or acidic solution as recommended by
the manufacturer; all peptides were soluble. Peptides were
designed using Peptgen [14] for maximal MHC binding
prediction.
PBMC were isolated from the peripheral blood on Ficoll-
Hypaque (Sigma, St. Louis, MO) by centrifugation. PBMC
were plated on IFN-γ-coated 96 well plates (Endogen,
Rockford, IL) at a density of 1 × 105 cells per well using
RPMI 1640 media with glutamine supplementation
(Sigma, St. Louis, MO) and 10% fetal calf serum. The pep-
tide stocks were diluted in RPMI media and added to the
wells at a final concentration of 14 μg/ml each. 5 μg/ml
PHA (Sigma, St. Louis, MO) was used as a stimulant con-
trol. The plates were incubated 24 hours at 37°C, 5% CO2
and developed according to the manufacturer's instruc-
tions. Briefly, the plates were washed then incubated with
INF-γ detection antibody (Endogen). After washing, plates
were incubated with streptavidin-AP conjugate secondary
antibody (Endogen). After a final washing, NBT/BCIP
substrate (Endogen) was added and the color was devel-
oped. Spots were counted manually using a dissection
microscope. In the initial screen, wells were considered
positive if total counts were greater than 10 spots per well.
Recombinant IFN-γ controls produced intense staining;
PHA control showed innumerable spots; media-only con-
trol produced less than 3 spots per well (data not shown).
For subject 6705A, the month 12 blood sample was ana-
lyzed by ELISPOT by plating PBMCs 1.3 × 105 or 5 × 104
per well in triplicate. HLA class I typing on whole blood
or PBMC fraction genomic DNA was performed at the
Washington University School of Medicine HLA labora-
tory using a commercial assay (Invitrogen) using PCR and
HLA-specific probe hybridization.
Results of class I typing are as follows [subject) HLA-A,
HLA-B, HLA-C]: 4A) A03/25, B18/35, Cw04/12; 52405A)
A02/*, B07/15, Cw03/15; 52605) A02/24, B35/40,
Cw03/04; 6105) A03/*, B50/57, Cw07/18; 6205A) A11/
30, B42/52, Cw12/17; 6205B) A02/24, B07/27, Cw01/07;
6605B) A02/03, B07/44, Cw05/07; 6605C) A02/*, B18/
57, Cw06/07; 6705A) A23/33, B15/58, Cw02/03; 2) A03/
23, B35/37, Cw02/07 (*represents likely homozygosity as
common A02 or A03 alleles but a rare second allele can-
not be excluded).
The IFN-γ ELISPOT assay is known to correlate with
cytokine flow cytometry-based methods and is a sensitive
test for antigen-specific T cell activity [15]. By this method,
we found the region around mutation K103N to be reac-
tive to T cells in 3 of the 10 subjects using 18-mer 103N
mutant peptides in an initial screen. Subjects 6205A and
6705A had significant responses to a mixture of LGIPH-
PAGLKKNKSVTVL plus GLKKNKSVTVLDVGDAYF (pep-
tides assayed together). Subject 2 had a significant
response to GLKKNKSVTVLDVGDAYF and a response
slightly above background for LGIPHPAGLKKNKSVTVL
(data not shown).
We next verified and characterized an epitope incorporat-
ing K103N in subject 6705A using PBMCs obtained 12
months after the initial ELISPOT assay. As shown in Figure
1, individual 18-mer mutant peptides LGIPH-
PAGLKKNKSVTVL and GLKKNKSVTVLDVGDAYF reacted
with the subject's T cells, confirming the previous mixed-
peptide result. Wild type peptide GLKKKKSVTVLDVG-
DAYF did not react. Furthermore, a 9-mer mutant peptide,
KKNKSVTVL, reacted significantly whereas the wild type
did not (Fig. 1). Finally, neither mutant nor wild type 9-
mers HPAGLKK(N/K)K displayed CTL activity (Fig. 1).
These results indicate that subject 6705A was able to
mount an anti-103N CTL response if 103N was properly
positioned within the epitope. The reactivity of such a
short peptide suggests that the response is due to CTL
activity [8].AIDS Research and Therapy 2006, 3:21 http://www.aidsrestherapy.com/content/3/1/21
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If HLA A or B is important for the 103N antiviral response
at RT amino acids 101–109 in subject 6705A, then candi-
date alleles for presentation of this peptide are A23, A33,
B15 or B58. Although the alleles were typed only to two
digits in this study, among A*2301, A*3301, B*1501 and
B*5801, A*2301 can be predicted to have the highest
binding affinity for KKNKSVTVL at a predicted IC50 of
613 nM using an smm prediction tool [16,17]. It is inter-
esting to note that subject 2 also carries an A23 allele and
demonstrated responses against this region.
Because of the relatively long half life of efavirenz,
patients who simultaneously discontinue combination
antiretroviral therapy are exposed to functional efavirenz
monotherapy [18]. Such monotherapy can result in the
rapid selection of K103N [19]. For subject 6705A, anti-
103N CTL activity may have contributed to suppression of
103N mutant virus replication, as reflected by the rela-
tively low levels of viremia prior to switching drug ther-
apy.
The emergence of K103N and other drug resistant variants
may be a dynamic process influenced by patient-specific
anti-HIV CTL activity. In support of this idea, interactions
between certain HLA subtypes, specific antiretroviral drug
exposures and HIV sequence diversity have been found
[20]. Another study found CTL responses against drug
resistant variants [21] but did not assess the RT 103 region
that we describe here. Characterizing more HLA subtypes
with regard to HIV epitopes incorporating drug resistance
mutations could lead to the design of therapeutic vaccines
or suggest tailored therapy against HIV.
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ELISPOT assay for CTL responses to RT 103 region peptides Figure 1
ELISPOT assay for CTL responses to RT 103 region peptides. Subject 6705A PBMCs were stimulated with wild type 
or mutant peptides as described in the text. RT position 103 is underlined. Error bars indicate standard deviations of assays 
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